Abstract:Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among early-onset AF patients (∼4%–11%), most notably for cardiomyopathy genes in which rare variants are considered clinically actionable. Genetic testing thus presents a promising opportunity to identify monogenetic defects linked to AF and inherited cardiac conditions, such as cardiomyopathy, and may contribute to prognosis and management in early-onset AF patients. A first step towards recognizing this monogenic contribution was taken with the Class IIb recommendation for genetic testing in AF patients aged 45 years or younger by the 2023 American College of Cardiology/American Heart Association guidelines for AF. By identifying pathogenic genetic variants known to underlie inherited cardiomyopathies and arrhythmia syndromes, a personalized care pathway can be developed, encompassing more tailored screening, cascade testing, and potentially genotype-informed prognosis and preventive measures. However, this can only be ensured by frameworks that are developed and supported by all stakeholders. Ambiguity in test results such as variants of uncertain significance remain a major challenge and as many as ∼60% of people with early-onset AF might carry such variants. Patient education (including pretest counselling), training of genetic teams, selection of high-confidence genes, and careful reporting are strategies to mitigate this. Further challenges to implementation include financial barriers, insurability issues, workforce limitations, and the need for standardized definitions in a fast-moving field. Moreover, the prevailing genetic evidence largely rests on European descent populations, underscoring the need for diverse research cohorts and international collaboration. Embracing these challenges and the potential of genetic testing may improve AF care. However, further research—mechanistic, translational, and clinical—is urgently needed. In people with early-onset atrial fibrillation (AF), an enrichment in pathogenic or likely pathogenic variants in cardiomyopathy and or/arrhythmia syndrome-associated genes is observed (see Figure 2 for more details). The diagnostic yield of capturing people with variants in these genes is higher with younger age, family history, structural or electrocardiogram (ECG) abnormalities (see Figure 1 for more details). Uncovering these high-risk individuals for heart failure enables personalized management that will need to comprehensively assess potential risks and benefits of genetic testing results. Some benefits include genotype-informed clinical assessment such as reinterpretation of borderline left ventricular hypertrophy in the setting of hypertrophic cardiomyopathy variants as well as genetic counselling and cascade testing of family members. Potential risks include the high likelihood of variants of uncertain significance that may lead to anxiety without informing healthcare decisions. Resource constraints in clinical settings might lead to further inequity for people without access to academic centres with the necessary infrastructure to offer such genetic testing services or genetic counselling (see Figure 3 for more details).

Molecular genetic screening after non-ischaemic sudden cardiac arrest and no overt cardiomyopathy in real life: A major tool for the aetiological diagnostic work-up

Prevalence and Electrophysiological Phenotype of Rare SCN5A Genetic Variants Identified in Unexplained Sudden Cardiac Arrest Survivors.

The Role of Next-Generation Sequencing in the Management of Patients with Suspected Non-Ischemic Cardiomyopathy after Syncope or Termination of Sudden Arrhythmic Death

Lessons learned from testing cardiac channelopathy and cardiomyopathy genes in individuals who died suddenly: A two‐year prospective study in a large medical examiner’s office with an in‐house molecular genetics laboratory and genetic counseling services

Whole-exome sequencing to identify causative variants in cases of sudden cardiac death below 50 years

Genetic Causes of Sudden Cardiac Arrest in the Community

Genetic testing for inherited arrhythmia syndromes and cardiomyopathies: results of the European Heart Rhythm Association survey

Genetic Testing in Brugada Syndrome: A 30-Year Experience

Actionable Variants of Unknown Significance in Inherited Arrhythmogenic Syndromes: A Further Step Forward in Genetic Diagnosis

Cardiogenetics: the role of genetic testing for inherited arrhythmia syndromes and sudden death

Cardiac Genetic Test Yields and Genotype-Phenotype Correlations from Large Cohort Investigated by Medical Examiner's Office

Abstract 14337: Identification of New Clinical Phenotypes of Sudden Cardiac Death Using Artificial Intelligence

Unexplained cardiac arrest: a tale of conflicting interpretations of KCNQ1 genetic test results

Comprehensive Phenotypic Characterization of Late Gadolinium Enhancement Predicts Sudden Cardiac Death in Coronary Artery Disease

C.1 Utility of genetic testing in the pre-surgical evaluation of children with drug-resistant epilepsy

The impact of the European Society of Cardiology guidelines and whole exome sequencing on genetic testing in hereditary cardiac diseases

Identifying barriers to genetic testing in subspecialty cardiac care

Genetic testing in early-onset atrial fibrillation

Abstract TP280: Monogenetic Stroke Syndrome Testing in Adults: A Single Center Experience

Multinational experience with next-generation sequencing: opportunity to identify transthyretin cardiac amyloidosis and Fabry disease

A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma